Ovarian steroidogenesis regulatory pathways

Ovarian steroidogenesis regulatory pathways encompass the complex biochemical and signaling processes responsible for the synthesis of steroid hormones, including estrogens, progestogens, and androgens, within the ovarian follicles. These pathways are primarily regulated by the hypothalamic-pituitary-gonadal (HPG) axis through the action of gonadotropins, specifically Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH), which act on G protein-coupled receptors in theca and granulosa cells (Source: StatPearls, PMID: 30252305). The process involves the transport of cholesterol into the mitochondria via the Steroidogenic Acute Regulatory (StAR) protein and subsequent conversion by a series of cytochrome P450 enzymes and hydroxysteroid dehydrogenases (Source: KEGG, map04913). Clinical disorders such as polycystic ovary syndrome (PCOS), endometriosis, and various forms of infertility often stem from the dysregulation of these steroidogenic enzymes or their upstream regulators (Source: NIH, PubMed). Pharmacological interventions targeting these pathways include aromatase inhibitors to block estrogen production, GnRH modulators to control gonadotropin release, and oral contraceptives to provide exogenous hormonal feedback (Source: Mayo Clinic). Understanding these pathways is essential for managing reproductive health and developing targeted therapies for hormone-dependent cancers and endocrine disorders.

Other names

Ovarian steroidogenesisFollicular steroidogenesisSteroid hormone biosynthesis pathwayHPG axis-mediated ovarian steroidogenesis

Drugs targeting these pathways function through several mechanisms: competitive inhibition of steroidogenic enzymes like aromatase (CYP19A1) to reduce estrogen levels; agonism or antagonism of GnRH receptors to suppress or stimulate the HPG axis; and modulation of nuclear hormone receptors (estrogen and progesterone receptors) to alter gene expression and feedback mechanisms (Source: PubChem, DrugBank).